Quick Read Cytokinetics launched FDA-approved MYQORZO in December 2025 with Q4 revenue of $17.75M beating consensus by 121%; ...

A biopharmaceutical company focused exclusively on metabolic dysfunction-associated steatohepatitis (MASH), having secured ...

Shares of Madrigal Pharmaceuticals (MDGL) traded sharply higher for the second straight session on Wednesday after Cantor Fitzgerald upgraded the company, arguing that the commercial rollout of its ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “The introduction of Rezdiffra as the first and only FDA-approved therapy in NASH marks a turning point for Madrigal and the NASH community.

Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the patent covering Rezdiffra™ (resmetirom), the only FDA-approved treatment for ...

Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) The Rezdiffra prescribing information does not include a liver biopsy requirement ...

Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal ...